Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2017-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor effect and safety of clinical
effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK)
for unresectable locally advanced pancreatic cancer.